Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
IPO Year: 2019
Exchange: NASDAQ
Website: hoththerapeutics.com
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
S-8 - Hoth Therapeutics, Inc. (0001711786) (Filer)
10-Q - Hoth Therapeutics, Inc. (0001711786) (Filer)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
ARS - Hoth Therapeutics, Inc. (0001711786) (Filer)
DEFA14A - Hoth Therapeutics, Inc. (0001711786) (Filer)
DEF 14A - Hoth Therapeutics, Inc. (0001711786) (Filer)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
10-Q - Hoth Therapeutics, Inc. (0001711786) (Filer)
424B3 - Hoth Therapeutics, Inc. (0001711786) (Filer)
EFFECT - Hoth Therapeutics, Inc. (0001711786) (Filer)
Aronnax to Determine the Maximum-Tolerated Dose (MTD) Post Intravenous Injection Followed by a Dose Range-Finding Phase of Hoth's Orphan Drug HT-KIT NEW YORK, Aug. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic. HT-KIT research, which was conducted at NC State University to evaluate the efficacy of HT-KIT in cancerous and non-cancerous cells, has demonstrated that HT-KIT effectively kills human
Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients. HT-ALZ's pre-clinical significance lies in its ability to demonstrate marked cognitive improvement and quality of life for subjects suffering from Alzheimer's disease The pre-clinical research shows compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment. NEW YORK, July 24, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopha
Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health NEW YORK, July 16, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). "We are very pleased to have received approval from these three world
Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary data NEW YORK, June 10, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia. BioNeMo provides researchers and developers a fast and easy way to build and integrate state-of-the-art generative AI applications across the entire drug discovery pipelin
NEW YORK, May 1, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the EF Hutton Annual Global Conference in New York, NY. To learn more about the EF Hutton Annual Global Conference please visit https://efhutton.com/conference/. About Hoth Therapeutics, Inc.Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a cataly
NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No. 333-269224). The gross proceeds to the Company from the exercise of the warrants are expected to be appr
Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has identified a promising new therapeutic candidate, culminating in a strategic patent filing. Capitalizing on Hoth Therapeutics' diverse portfolio, Merveil
HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease. NEW YORK, March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic. Targeting the Substance P/Neurokinin 1 Receptor pathway, HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease. This pioneering study, conducted by
NEW YORK, Feb. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that it will continue its work with Venable, LLP to develop and protect its intellectual property. Venable is an American Lawyer Global 100 law firm that serves as primary counsel to a worldwide clientele of large and mid-sized organizations and nonprofits and individuals. With more than 900 professionals across the country, the firm strategically advances its clients' objectives in the United States and around the globe. Venable advises clients on a broad range of topics, including the full range of intellectual property disciplines.
Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University. The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The upcoming study will use th
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company
TSLA: -8.8% | Tesla shares are trading lower following mixed Q2 earnings. The company also said it expects 2024 vehicle volume growth lower than 2023. HOTH: 95% | Hoth Therapeutics signs Agreement With LTS Therapy Systems To Develop And Manufacture The HT-ALZ Oral Film Prototype In Alzheimer's Disease PRG: 14% | PROG shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company raised its FY24 guidance above estimates.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 price target.
Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health
Gainers Holdco Nuvo Group DG (NASDAQ:NUVO) shares increased by 21.5% to $1.92 during Wednesday's after-market session. The company's market cap stands at $63.8 million. Entero Therapeutics (NASDAQ:ENTO) shares moved upwards by 8.69% to $2.25. The company's market cap stands at $6.1 million. OneMedNet (NASDAQ:ONMD) shares moved upwards by 7.4% to $1.45. The market value of their outstanding shares is at $34.5 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 5.92% to $0.29. Nutex Health (NASDAQ:NUTX) stock increased by 5.53% to $0.57. The market value of their outstanding shares is at $28.3 million. Inspire Veterinary (NASDAQ:IVP) stock increased by 5.05%
Shares of Contango Ore, Inc. (NYSE:CTGO) fell sharply during Tuesday's session after the company announced pricing of $15 million underwritten public offering. Contango Ore shares dipped 18.4% to $20.34 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Trio Petroleum Corp. (NYSE:TPET) shares jumped 88.2% to $0.4254 after the company completed its first two exploratory wells. Airship AI Holdings, Inc. (NASDAQ:AISP) shares climbed 32.5% to $4.1599. Airship AI announced a six-figure sole-source contract award within the Department of Justice for Acropolis Enterprise Video and Data Management Platform. Blue World Acquisition Corporation (NASDAQ
Shares of Calavo Growers, Inc. (NASDAQ:CVGW) rose sharply in today's pre-market trading after the company reported second-quarter financial results. Total net sales surged 16.5% year-over-year to $184.4 million during the quarter. Adjusted net income surged to $8.9 million, or 50 cents per diluted share, from $5.1 million, or 29 cents per diluted share for the year-ago quarter. Calavo Growers shares jumped 11.6% to $27.90 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers ShiftPixy, Inc. (NASDAQ:PIXY) rose 41.1% to $2.06 in today's pre-market trading. Nauticus Robotics, Inc. (NASDAQ:KITT) shares rose 27.2% to $0.2938 in pre-
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)